Andrew Woo
Neurology · Santa Monica, CANPI 1750419560
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $199,979 of the $273,356 with a category attached, or 73.2%. 56 manufacturers reported payments, led by Sanofi at 34.8% of the total. Reporting peaked in 2019 at $172,095 and has fallen 99.3% since, to $1,227 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,036 payments — averaging $263.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$95K
- Novartis$66K
- Genentech USA, Inc.$64K
- EMD Serono, Inc.$21K
- Bristol Myers Squibb$6K
- E.r. Squibb & Sons, L.L.C.$4K
- plus $17K from 50 others
What the payments were for
- Consulting fees$28,47910%
- Speaking & faculty fees$199,97973%
- Travel & lodging$22,3318%
- Food & beverage$22,3198%
- Education$2480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$273,356 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 11 | $94,646 |
| Glatiramer Acetate | 12 | $17,971 |
| FingolimodFingolimod Hcl | 15 | $16,481 |
| Rasagiline Mesylate | 21 | $5,692 |
| Rivastigmine | 11 | $2,473 |
| Duloxetine Hcl | 89 | $1,565 |
| Carbamazepine | 20 | $1,368 |
| Gabapentin | 120 | $1,282 |
| Memantine Hcl | 36 | $1,071 |
| Dalfampridine ErDalfampridine | 18 | $853 |
| Sumatriptan Succinate | 24 | $772 |
| RizatriptanRizatriptan Benzoate | 45 | $705 |
| Escitalopram Oxalate | 47 | $688 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 34 | $632 |
| Topiramate | 12 | $604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Upsher-smith Laboratories LLCTopiramate | $474 | $60412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Santa Monica
- David KudrowSanta Monica$532K
- Santosh KesariSanta Monica$397K
- Danny BenmosheSanta Monica$268K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.